Engineered Transaminase Polypeptides for Chiral Amine Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transaminases used for catalyzing reactions to prepare chiral amine compounds face issues such as instability under industrially useful process conditions and narrow substrate recognition, limiting their commercial application.
Innovation Solution
Engineered polypeptides with transaminase activity are developed, featuring specific amino acid residue differences that enhance solvent and thermal stability, activity, stereoselectivity, and product tolerance, allowing for efficient conversion of large ketone substrate compounds to their corresponding chiral amine products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type transaminases are used for catalyzing reactions to prepare chiral amine compounds, then the reaction can proceed with natural substrate recognition, but the enzyme exhibits instability under industrially useful process conditions and narrow substrate recognition
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (e.g., positions 86, 88, 107, 113, 147, 155, 233, 286, 312, 316, 383, 415, 417, 434) to optimize both enzyme stability and substrate recognition. These residue changes alter the enzyme's physical and chemical properties, enabling it to maintain stability under industrial conditions while expanding substrate scope.
Solution Approach 2:
The engineered transaminase represents a composite structure combining the natural enzyme framework with strategically introduced amino acid modifications. This composite approach integrates the inherent catalytic activity of the wild-type enzyme with enhanced stability and broadened substrate recognition capabilities through multiple targeted mutations.
2Use of energy by moving object
If wild-type transaminases are used, then the enzyme maintains natural catalytic activity, but it shows limited solvent and thermal stability
Solution Approach 1:
The patent employs parameter changes by modifying specific amino acid residues to enhance thermal stability while preserving catalytic activity. The residue changes at positions such as 86, 88, 107, 113, and others alter the enzyme's thermal response characteristics, allowing it to maintain activity at higher temperatures and in various solvent conditions.
3Manufacturing precision
If wild-type transaminases are used, then the enzyme shows natural substrate specificity, but it lacks high diastereomeric excess in product formation
Solution Approach 1:
The patent applies parameter changes by introducing amino acid substitutions at key positions (e.g., 86, 88, 107, 113, 147, 155, 233, 286, 312, 316, 383, 415, 417, 434) that enhance the enzyme's stereoselectivity. These modifications optimize the active site geometry and interactions, resulting in high diastereomeric excess while maintaining broad substrate recognition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered transaminase polypeptides demonstrate increased activity, high stereoselectivity, and improved stability, enabling the efficient conversion of a range of ketone substrate compounds to chiral amine products with high diastereomeric excess under various reaction conditions.
Implementation Method 1
Transaminases (E.C. 2.6.1) catalyze the transfer of an amino group, a pair of electrons, and a proton from a primary amine of an amino donor substrate to the carbonyl group of an amino acceptor molecule
Data Source
AI summary
The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.